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Poster Session I S259(day -13 to -11), and antithymocyte globulin (rabbit) 7.5 mg/kg(day
-3 to -1). The infused cell dose was 10.71  107/kg nucleated cells
(range from 6.5 to 17 107/kg nucleated cells. Age range from 1.5
year to 7 year. Weight range from10.5 t0 17 kg.
Failure of engraftment is a frequent complication following unre-
lated Umbilical Cord haematopoietic stem cell transplantation for
patients with thalassemia because of Limited dose of stem cells,
multiple transfusions and hypercellular marrow. We tried second
transplant with two unrelated cord blood units for primary graft fail-
ure after cord blood transplantation in one patient. The retransplant
recipients were preconditioned with i.v Cy 120 mg/kg (day -3 to -2) .
Results:Two patients engrafted promptly with 100% donor chime-
rism out of 6 children (33.33%). One child has 50 % donor chime-
rism on day 15. The absolute neutrophil count first exceeded 0.5 
109/l on day 17, and the patient became red cell- and platelet-
independent on days 34 and 49, respectively. All patients engrafted
at a median of 17 days (range 12–19). One patient is transfusion
free for 32 months while second patient is transfusion free for 13
months. There is no transplant related mortality (TRM).
The post transplant complications were mild hepatic veno-
occlusive disease, acute GVHD grade II, and CMV interstitial
pneumonia. The chronic GVHD was limited and could be con-
trolled by Methylprednisolone combined with Mycophenolate.
Conclusions: As there is no marrow donor registry in India, Umbil-
ical cord blood transplantation is a good alternative and is possible. It
should be considered for patients with beta-thalassemia major who
lack traditional bone marrow donors. Transplant should be done af-
ter 18months of age as earliest. Dose of stem cells is the most impor-
tant factor for engraftment. Results can be improved further with
more experience.288
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Diagnostic endoscopic procedures are considered part of theman-
agement of children post haematopoietic stem cell transplant
(HSCT) when there is a clinical suspision of gastrointestinal (GI)
acute graft-versus-host disease (aGvHD). However, GI endoscopy
and biopsy in children is invasive, usually performed in main operat-
ing room under general anesthesia with the need for blood product
support in newly engrafted fragile patients. The diagnosis of GI
aGVHD is mostly made on clinical criteria based on stool volume,
ileus and bleeding. Our objective in this study was to review the ben-
efits of GI endoscopies and biopsies in the management of GI
aGVHD in children post HSCT.
From January 2000 to December 2009, 450 children underwent
allogeneic HSCT at the hospital for Sick Children in Toronto. Se-
venty-nine (17.5%) patient underwent endoscopy and GI biopsy
for suspicion of GI aGVHD. The majority were boys, . 10 years
of age with underlying haematological malignancies. Donor sources
were: Unrelated 50; related 29. Stem cell source were; BM60%, cord
25% and PBSC 15%. Themajority received meyloablative regimens
with cyclosporine and methotrexate (or methylprednisolone for
cords) for GvHD prophylaxis. All the patients engrafted within 8-
49 days. Clinical grading of GI aGVHD was, I in 5 patients, II in
39, III in 23 and grade IV in 12 patients. All patients tolerated endos-
copy and GI biopsy well except for one patient who developed duo-
denal hematoma requiring prolonged GI rest.
GI biopsy confirmed aGVHD in 49 (62%) patients and results
were negative in 30(38%) patients. Eight patients had positive viral
studies from the biopsy (adeno 5, CMV 1, HHV6 1 and EBV 1)
and one biopsy was positive for Candida. Thirty- two (40%) patients
have started treatment for GI aGvHD before the biopsy was done
based on clinical criteria, while 24/79 (30%) patients started treat-
ment after the biopsy results. Fifteen (19%) patients required 2nd
line therapy for progressive GI GvHD based on clinical non re-
sponse criteria. Twenty-nine (36%) patients died; 20 due to TRM
and GvHD complications and 9 children died because of recurrence
of their underlying malignancy.Conclusion: GI biopsy results after clinical suspicion of aGvHD in
children post allogeneic HSCT led to starting or altering therapy in
30% of the patients. Patients who were already on therapy for GI
GvHD, biopsy results did not alter their management and escalating
therapy was based on clinical progression.289
MYELO-ABLATIVE EXPOSURE OF BUSULFAN+FLUDARABINE IN
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Background: Busulfan (Bu) as myeloablative agent is used in condi-
tioning prior to HSCT mainly in combination with cyclophospho-
mide (Cy). In pediatric patients receiving BuCy4, we recently
found a clear association between busulfan-exposure and outcomes:
overall survival (OS) and event free survival (EFS). Toxicity leading
to morbidity and associated mortality remains a limiting factor in
HSCT. Comparative studies in adults showed a favorable toxicity
profile for busulfan+fludarabine (BuFlud) compared to BuCy. In
paediatrics, limited data is available regarding this regimen. BuFlud
was recently (2009) introduced in our center to replace the BuCy4
regimen for myeloid malignancies and all non-malignant indica-
tions. We compared the outcomes with our BuCy4 historic controls
transplanted between 2005-March 2009.
Methods: Fludarabine 40mg/m2 was given in 1 hour prior to a 3
hour infusion of once daily busulfan. Busulfan dose targeting, based
on therapeutic drug monitoring was performed before the second
dose. The target area under the curve (AUC) for Bu was . 74
mg*h/L (cummulative) in both groups Thymoglobuline 10mg/kg
was given in the unrelated donor setting. Primary endpoints were
EFS and OS. Secondary endpoints: acute graft-versus-host disease
(aGvHD), VOD, duration of the neutropenic period and the number
of erythrocyte and thrombocyte transfusions. A risk factor analysis
was performed using univariable and multivariable COX regression.
Results: 29 patients (19 unrelated cord blood, 8 MSD and 2 MUD)
were included in the BuFlud group (median follow up 219 days;
range 42-593) and 44 in the BuCy4 group (975 days; range 6-
1950). The groups were comparable regarding donor source, age,
gender, indication for HSCT and match-grade. EFS and OS in Bu-
Flud and BuCy was 75% vs 71% (NS) and 82% vs. 73% (NS), resp.
Probablility on neutrophile engraftment (day60) was 92% (BuCy4)
and 94% (BuFlu) No difference in aGvHD ($ grade 2) was found,
23%: BuFlu vs 30%: BuCy4. Less VODwas seen in the BuFlu group
(3% vs 18%: p5 0.012). The duration of neutropenia wasmedian 12
days in the BuFlud group compared to 20.5 days in BuCy4 (p 5
0.012). The median number of erythrocyte transfusion in BuFlu
was 1 (range 1-13) vs. 5 (0-22) in BuCy4 (p5 0.04) and thrombocyte
infusions 4 (range 0-33) vs 10 (range 2-44: p 5 0,02), resp.
Conclusions: Busulfan+fludarabine showed to be as effective but
a lesser toxic regimen than BuCy4. Further follow up and extension
of the series is needed.290
ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)
FOR PEDIATRIC ACUTE MYELOGENOUS LEUKEMIA (AML): MATCHED
SIBLING VS UNRELATED CORD BLOOD (UCB) DONOR
Choudhury, N.G., Duerst, R.E., Chaudhury, S., Tse, W.,
Schneiderman, J., Kletzel, M. Children’s Memorial Hospital, Chicago, IL
Indications for allogeneic HSCT in treatment of pediatric AML
have varied with changing efficacy of conventional AML regimens,
improved understanding of ‘‘high-risk’’ biology, as determined by
minimal residual disease and/or cytogenetic alterations in the leuke-
mic clone and progenitor cell sources. We report the experience of
40 children/young adult patients (pts) with primary AML undergo-
ing initial allogeneic HSCT at Children’s Memorial Hospital be-
tween January 2000 and December 2008 comparing the results of
the UCB recipients (n 5 22) with recipients of matched sibling
(msib) marrow/peripheral blood stem cells (m/PBSC, n 5 18).
